Glox Therapeutics Raises £4.3m Seed Funding To Combat Drug-Resistant Bacteria With Precision Antimicrobials
Glasgow, UK, 14 Nov, 2023: Glox Therapeutics, the company at the forefront of crafting precise antibiotic treatments derived from natural bacteriocins, has secured £4.3 million in initial funding. This funding aims to drive the development of highly targeted therapies aimed specifically at combating antibiotic-resistant Gram-negative bacteria. The company plans